Defendant Name: Chembio Diagnostics, Inc.

Defendant Type: Public Company
SIC Code: 6282
CUSIP: 16357220

Document Reference: 33-11163

Document Details

Legal Case Name In the Matter of Chembio Diagnostics, Inc.
Document Name Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933, Making Findings, and Imposing a Cease-and-Desist Order
Document Date 02-Mar-2023
Document Format Administrative Proceeding
File Number 3-21320
Allegation Type Securities Offering
Document Summary The Commission stated: "This matter involves a material misrepresentation made by Chembio concerning the performance of a COVID-19 antibody test the company developed and marketed during the spring of 2020 (“COVID-19 Test”)."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Cooperation Before the Resolution
Remedial Acts or Efforts Before the Resolution
Monetary Penalties:

Civil Penalty

Individual:     $500,000.00 Shared:    

Related Documents:

33-11163-s 02-Mar-2023 Administrative Summary
SEC Charges Medical Test Manufacturer with Misrepresenting Performance of Covid-19 Test
The SEC "announced settled charges against Chembio Diagnostics, Inc., a New York-based manufacturer of medical diagnostic tests, for making a false and misleading statement about the performance of its COVID-19 antibody test shortly before a securities offering in which it raised millions of dollars."